Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

Discover a trial that included 135 adults, randomly assigned to receive either inebilizumab or a placebo for a 52-week ...

KEY POINTS A 72-year-old man presented to the emergency department with a 2-week history of hypotension, postural dizziness, and muscle weakness. He had a medical history of HIV, lipodystrophy, ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Sivakumar VijayaraghavaluThe formative years of childhood, especially from birth to age five, lay the foundation for lifelong health and well-being. Unfortunately, when young children are subjected to ...

The STOX Suite is a digital platform that standardizes the measurement of steroid-toxicity, enabling researchers and ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients with ...

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...